The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism
Abstract
BACKGROUND: Low molecular weight heparins (LMWH) have been shown to be effective and safe in preventing venous thromboembolism (VTE), and may also be effective for the initial treatment of VTE. OBJECTIVES: To determine the effect of LMWH compared with unfractionated heparin (UFH) for the initial treatment of VTE. SEARCH STRATEGY: Trials were identified from the Cochrane Peripheral Vascular Diseases Group's Specialised Register, CENTRAL and LILACS. Colleagues and pharmaceutical companies were contacted for additional information. SELECTION CRITERIA: Randomised controlled trials comparing fixed dose subcutaneous LMWH with adjusted dose intravenous or subcutaneous UFH in people with VTE. DATA COLLECTION AND ANALYSIS: At least two reviewers assessed trials for inclusion and quality, and extracted data independently. MAIN RESULTS: Twenty-two studies were included (n = 8867). Thrombotic complications occurred in 151/4181 (3.6%) participants treated with LMWH, compared with 211/3941 (5.4%) participants treated with UFH (odds ratio (OR) 0.68; 95% confidence intervals (CI) 0.55 to 0.84, 18 trials). Thrombus size was reduced in 53% of participants treated with LMWH and 45% treated with UFH (OR 0.69; 95% CI 0.59 to 0.81, 12 trials). Major haemorrhages occurred in 41/3500 (1.2%) participants treated with LMWH, compared with 73/3624 (2.0%) participants treated with UFH (OR 0.57; 95% CI 0.39 to 0.83, 19 trials). In eighteen trials, 187/4193 (4.5%) participants treated with LMWH died, compared with 233/3861 (6.0%) participants treated with UFH (OR 0.76; 95% CI 0.62 to 0.92). Nine studies (n = 4451) examined proximal thrombosis; 2192 participants treated with LMWH and 2259 with UFH. Subgroup analysis showed statistically significant reductions favouring LMWH in thrombotic complications and major haemorrhage. By the end of follow up, 80 (3.6%) participants treated with LMWH had thrombotic complications, compared with 143 (6.3%) treated with UFH (OR 0.57; 95% CI 0.44 to 0.75). Major haemorrhage occurred in 18 (1.0%) participants treated with LMWH, compared with 37 (2.1%) treated with UFH (OR 0.50; 95% CI 0.29 to 0.85). Nine studies (n = 4157) showed a statistically significant reduction favouring LMWH with respect to mortality. By the end of follow up, 3.3% (70/2094) of participants treated with LMWH had died, compared with 5.3% (110/2063) of participants treated with UFH (OR 0.62; 95% CI 0.46 to 0.84). REVIEWERS' CONCLUSIONS: LMWH is more effective than UFH for the initial treatment of VTE. LMWH significantly reduces the occurrence of major haemorrhage during initial treatment and overall mortality at follow up.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
Decousus, H., Leizorovicz, A., Parent, F., Page, Y., Tardy, B., Girard, P., Laporte, S., Faivre, R., Charbonnier, B., Barral, F.-G., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802123380701 · Cited by 1,702
Levine, M., Gent, M., Hirsh, J., Leclerc, J., Anderson, D., Weitz, J., Ginsberg, J., Turpie, A. G., Demers, C., Kovacs, M., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341101 · Cited by 1,192
Koopman, M. M. W., Prandoni, P., Piovella, F., Ockelford, P. A., Brandjes, D. P. M., van der Meer, J., Gallus, A. S., Simonneau, G., Chesterman, C. H., Prins, M. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341102 · Cited by 1,111
Self-citationHirsh, J., & Levine, M. (1992) · Blood · doi:10.1182/blood.v79.1.1.bloodjournal7911 · Cited by 894
Oates, J. A., Wood, A. J. J., & Hirsh, J. (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242206 · Cited by 830
Low-Molecular-Weight Heparin in the Treatment of Patients with Venous Thromboembolism
(1997) · New England Journal of Medicine · doi:10.1056/nejm199709043371001 · Cited by 784
Simonneau, G., Sors, H., Charbonnier, B., Page, Y., Laaban, J.-P., Azarian, R., Laurent, M., Hirsch, J.-L., Ferrari, E., Bosson, J.-L., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709043371002 · Cited by 782
Hull, R. D., Raskob, G. E., Hirsh, J., Jay, R. M., Leclerc, J. R., Geerts, W. H., Rosenbloom, D., Sackett, D. L., Anderson, C., Harrison, L., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198610303151801 · Cited by 722
Hull, R. D., Raskob, G. E., Pineo, G. F., Green, D., Trowbridge, A. A., Elliott, C. G., Lerner, R. G., Hall, J., Sparling, T., Brettell, H. R., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199204093261502 · Cited by 700
Nurmohamed, M. T., Buller, H. R., Dekker, E., Hommes, D. W., Rosendaal, F. R., Briet, E., Rosendaal, F. R., & Vandenbroucke, J. P. (1992) · The Lancet · doi:10.1016/0140-6736(92)93223-a · Cited by 668
Basu, D., Gallus, A., Hirsh, J., & Cade, J. (1972) · New England Journal of Medicine · doi:10.1056/nejm197208172870703 · Cited by 661
HULL, R. D., HIRSH, J., CARTER, C. J., JAY, R. M., DODD, P. E., OCKELFORD, P. A., COATES, G., GILL, G. J., TURPIE, A. G., DOYLE, D. J., et al. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-6-891 · Cited by 645
Prandoni, P., Carta, M., Cogo, A., Ruol, A., Vigo, M., Casara, D., Lensing, A. W. A., Büller, H. R., & ten Cate, J. W. (1992) · The Lancet · doi:10.1016/0140-6736(92)91054-c · Cited by 583
Self-citationHeparin for 5 Days as Compared with 10 Days in the Initial Treatment of Proximal Venous Thrombosis
Hull, R. D., Raskob, G. E., Rosenbloom, D., Panju, A. A., Brill-Edwards, P., Ginsberg, J. S., Hirsh, J., Martin, G. J., & Green, D. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005033221802 · Cited by 505
Brandjes, D. P. M., Heijboer, H., Büller, H. R., de Rijk, M., Jagt, H., & ten Cate, J. W. (1992) · New England Journal of Medicine · doi:10.1056/nejm199211193272103 · Cited by 480
Merli, G., Spiro, T. E., Olsson, C.-G., Abildgaard, U., Davidson, B. L., Eldor, A., Elias, D., Grigg, A., Musset, D., Rodgers, G. M., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-3-200102060-00009 · Cited by 362
Unexpected High Prevalence of Silent Pulmonary Embolism in Patients with Deep Venous Thrombosis
Huisman, M. V., Büller, H. R., ten Cate, J. W., van Royen, E. A., Vreeken, J., Kersten, M.-J., & Bakx, R. (1989) · Chest · doi:10.1378/chest.95.3.498 · Cited by 311
Gallus, A., Tillett, J., Jackaman, J., Mills, W., & Wycherley, A. (1986) · The Lancet · doi:10.1016/s0140-6736(86)91431-5 · Cited by 305
Monreal, M., Lafoz, E., Olive, A., del Rio, L., & Vedia, C. (1994) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1642376 · Cited by 299
Douketis, J. D., Foster, G. A., Crowther, M. A., Prins, M. H., & Ginsberg, J. S. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.22.3431 · Cited by 269
Self-citationLindmarker, P., Holmström, M., Granqvist, S., Johnsson, H., & Lockner, D. (1994) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1648836 · Cited by 210
Low-Molecular-Weight Heparin vs Heparin in the Treatment of Patients With Pulmonary Embolism
Hull, R. D. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.2.229 · Cited by 200
Breddin, H. K., Hach-Wunderle, V., Nakov, R., & Kakkar, V. V. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103013440902 · Cited by 195
Handeland, G. F., Abildgaard, U., Holm, H. A., & Arnesen, K. E. (1990) · European Journal of Clinical Pharmacology · doi:10.1007/bf00280041 · Cited by 181
Collins, R., Gray, R., Godwin, J., & Peto, R. (1987) · Statistics in Medicine · doi:10.1002/sim.4780060308 · Cited by 178
Low-Molecular-Weight Heparin in the Treatment of Patients With Venous Thromboembolism
(1998) · Journal of Urology · doi:10.1016/s0022-5347(01)63665-6 · Cited by 171
Ninet, J., Bachet, P., Prandoni, P., Ruol, A., Vigo, M., Barret, A., Mericq, O., Boneu, B., Janvier, G., Duroux, P., et al. (1991) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1647660 · Cited by 148
Bratt, G., Åberg, W., Johansson, M., Törnebohm, E., Granqvist, S., & LOCKNER, D. (1990) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1647348 · Cited by 147
Łopaciuk, S., Meissner, A. J., Filipecki, S., Zawilska, K., Sowier, J., Ciesielski, L., Bielawiec, M., Głowiński, S., Częstochowska, E., & others (1992) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1656309 · Cited by 145
Fiessinger, J., Fernández, M. F. L., Gatterer, E., Granqvist, S., Kher, A., Olsson, C. G., & Söderberg, K. (1996) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1650553 · Cited by 136
van den Belt, A., Prins, M. H., Lensing, A. W. A., Castro, A., Clark, O., Atallah, A., & Burihan, E. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001100 · Cited by 121
Self-citationvan den Belt, A., Prins, M., Gallus, A., Büller, H., Bossuyt, P., & for the TASMAN Study Group (1998) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614975 · Cited by 90
Self-citationde Valk, H. W., Banga, J. D., Wester, J. W. J., Brouwer, C. B., van Hessen, M. W. J., Meuwissen, O. J. A. T., Hart, H. C., Sixma, J. J., & Nieuwenhuis, H. K. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-1-199507010-00001 · Cited by 88
Nicolaides, A. N., Cesarone, M. R., LAURORA, G., Sanctis, M. T. D., INCANDELA, L., Barsotti, A., Corsi, M., Vasdekis, S. N., Christopoulos, D., Lennox, A., et al. (1999) · Angiology · doi:10.1177/000331979905001001 · Cited by 73
Schmidt, J.-O., Koppenhagen, K., Tolle, A., Huisman, M. V., Buller, H. R., Harenberg, J., & the EASTERN Investigators (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613886 · Cited by 69
Kirchmaier, C. M., Wolf, H., Schäfer, H., Ehlers, B., & Breddin, H. K. (1998) · PubMed · Cited by 57
Simonneau, G. (1993) · Archives of Internal Medicine · doi:10.1001/archinte.153.13.1541 · Cited by 42
Cost for Inpatient Care of Venous Thrombosis: A Trial of Enoxaparin vs Standard Heparin
de Lissovoy, G., Yusen, R. D., Spiro, T. E., Krupski, W. C., Champion, A. H., & Sorensen, S. V. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.20.3160 · Cited by 39
Findik, S., Erkan, M. L., Selçuk, M. B., Albayrak, S., Atici, A. G., & Doru, F. (2002) · Respiration · doi:10.1159/000064023 · Cited by 38
Koppenhagen, K., Tolle, A., Kemkes‐Matthes, B., Gräve, M., Pátek, F., Drexler, M., Siemens, H.-J. G., Harenberg, J., Weidinger, G., Brom, J., et al. (2003) · Thrombosis and Haemostasis · doi:10.1160/th02-09-0061 · Cited by 38
Cited by
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Konstantinides, S. V., Meyer, G., Becattini, C., Bueno, H., Geersing, G.-J., Harjola, V.-P., Huisman, M. V., Humbert, M., Jennings, C. S., Jiménez, D., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz405 · Cited by 4,916
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism
Authors/Task Force Members, Konstantinides, S. V., Torbicki, A., Agnelli, G., Danchin, N., Fitzmaurice, D., Galiè, N., Gibbs, J. S. R., Huisman, M. V., Humbert, M., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu283 · Cited by 3,128
Jaff, M. R., McMurtry, M. S., Archer, S. L., Cushman, M., Goldenberg, N., Goldhaber, S. Z., Jenkins, J. S., Kline, J. A., Michaels, A. D., Thistlethwaite, P., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318214914f · Cited by 2,229
Metadata
- Authors
- van Dongen, C. J., van den Belt, A. G., Prins, M. H., & Lensing, A.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2004-10-18
- Issue
- 4
- Pages
- CD001100-CD001100
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W4230743743
- Cited by
- 433
- References
- 41
- Type
- reference entry
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.